<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0752304" disease_type="Disease or Syndrome" abbrv="">Hypoxic-ischaemic brain injury</z:e> at birth is associated with 1-3/1000 cases of moderate to severe <z:hpo ids='HP_0001298'>encephalopathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Previously, we have shown that connexin 43 hemichannel blockade, with a specific mimetic <z:chebi fb="7" ids="16670">peptide</z:chebi>, reduced the occurrence of <z:hpo ids='HP_0001250'>seizures</z:hpo>, improved recovery of EEG power and sleep state cycling, and improved cell survival following global <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, we examined the dose response for intracerebroventricular mimetic <z:chebi fb="7" ids="16670">peptide</z:chebi> infusion (50 μmol/kg/h for 1 h, followed by 50 μmol/kg/24 h (low dose) or 50 μmol/kg/h for 25 h (high dose) or vehicle only (control group), starting 90 min after the end of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>), following global <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e>, induced by 30 min bilateral carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp>, in near-term fetal sheep (128 ± 1 days gestation) </plain></SENT>
<SENT sid="3" pm="."><plain>Both <z:chebi fb="7" ids="16670">peptide</z:chebi> infusion groups were associated with a transient significant increase in EEG power between 2-12 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-low dose group showed a significant recovery of EEG power from day five compared to the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-vehicle and -high dose groups </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, the high dose infusion was associated with greater secondary increase in impedance (brain cell swelling), as well as a trend towards a greater increase in <z:chebi fb="4" ids="24996">lactate</z:chebi> concentration and mortality </plain></SENT>
<SENT sid="6" pm="."><plain>These data suggest that higher doses of connexin mimetic <z:chebi fb="7" ids="16670">peptide</z:chebi> are not beneficial and may be associated with adverse outcomes, most likely attributable to uncoupling of connexin 43 gap junctions leading to dysfunction of the astrocytic syncytium </plain></SENT>
</text></document>